Acquiring Company
iBio
Acquired Company
RubrYc Therapeutics, Inc.
New YorkSan RamonManufacturingBiotechnologyBiotechnologyHealth CareScience And EngineeringDescription
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. (“RubrYc”) after it entered into a definitive asset purchase agreement (the “Purchase Agreement”). The transaction marks another important step toward iBio’s mission to bring more – and better – immunotherapies to the clinic, faster, with its continued transformation into a biopharmaceutical discovery and development company.
Quick answer
iBio is acquiring RubrYc Therapeutics, Inc., announced September 21, 2022. iBio is based in New York, New York, United States.
- Who acquired RubrYc Therapeutics, Inc?
- iBio agreed to acquire RubrYc Therapeutics, Inc. on September 21, 2022.
- How much did iBio pay for RubrYc Therapeutics, Inc?
- The deal value was not disclosed.
- What does iBio do?
- iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases.
- Where are iBio and RubrYc Therapeutics, Inc. based?
- iBio is based in New York, New York, United States. RubrYc Therapeutics, Inc. is based in San Ramon, California, United States.
- Who are the decision-makers at iBio?
- Fundz holds 2 contacts at iBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- Geistlich Pharma North America, Inc. Acquires Lynch Biologics, Llc, A Biologics And Tissue Engineering Company (October 27, 2022)
- Collagen Matrix Acquires Polyganics (October 5, 2022)
- Solesis Acquires Polyzen, Expanding Film And Coating Capabilities (November 2, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
- Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio (August 17, 2022)
Who to call at iBio, and when
When iBio changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day iBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at iBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at iBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment iBio makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired RubrYc Therapeutics, Inc.?
RubrYc Therapeutics, Inc. was acquired by iBio, based in New York. The deal was reported on September 21, 2022. iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio is publicly traded (IBIO) and operates in Manufacturing.
When did iBio acquire RubrYc Therapeutics, Inc.?
iBio's acquisition of RubrYc Therapeutics, Inc. was reported on September 21, 2022. iBio, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does RubrYc Therapeutics, Inc. do?
A San Ramon, CA-based biotherapeutics discovery company. It is privately held, operating in Biotechnology, and is based in San Ramon.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.